Myriad Genetics (MYGN) Net Income towards Common Stockholders: 2009-2025
Historic Net Income towards Common Stockholders for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$27.4 million.
- Myriad Genetics' Net Income towards Common Stockholders fell 23.98% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of -$127.3 million for FY2024, which is 51.65% up from last year.
- Myriad Genetics' Net Income towards Common Stockholders amounted to -$27.4 million in Q3 2025, which was up 91.71% from -$330.5 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Net Income towards Common Stockholders registered a high of $24.6 million during Q3 2021, and its lowest value of -$330.5 million during Q2 2025.
- In the last 3 years, Myriad Genetics' Net Income towards Common Stockholders had a median value of -$36.7 million in 2024 and averaged -$68.1 million.
- In the last 5 years, Myriad Genetics' Net Income towards Common Stockholders spiked by 261.84% in 2021 and then slumped by 800.54% in 2025.
- Over the past 5 years, Myriad Genetics' Net Income towards Common Stockholders (Quarterly) stood at -$7.6 million in 2021, then slumped by 456.58% to -$42.3 million in 2022, then rose by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then dropped by 23.98% to -$27.4 million in 2025.
- Its Net Income towards Common Stockholders was -$27.4 million in Q3 2025, compared to -$330.5 million in Q2 2025 and -$100,000 in Q1 2025.